Abstract
No public abstract is available from the verified source records.
Samaneh Toutounchian
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Silencing of glucocerebrosidase gene in drosophila enhances the aggregation of Parkinson’s disease associated α-synuclein mutant A53T and affects locomotor activity
10.3389/fnins.2018.00081 · 2018
Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease
10.1002/mds.10390 · 2003
Initiation of Parkinson’s disease from gut to brain by δ-secretase
10.1038/s41422-019-0241-9 · 2020
Role of GABA pathway in motor and non-motor symptoms in Parkinson’s disease: a bidirectional circuit
10.1186/s40001-024-01779-7 · 2024
Chaperone-mediated autophagy markers in Parkinson disease brains
10.1001/archneurol.2010.198 · 2010
Unresolved referenced work
Kept as external metadata until matched
Gene therapy for Parkinson’s disease, an update
10.3233/jpd-181331 · 2018
Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies
1998
Gene therapy with AAV 2‐ CDNF provides functional benefits in a rat model of P arkinson’s disease
10.1002/brb3.117 · 2013
Gene Therapy for Parkinson’s Disease: preclinical Evaluation of Optimally Configured TH:CH1 Fusion for Maximal Dopamine Synthesis
10.1016/j.omtm.2019.07.002 · 2019
Molecular and functional architecture of striatal dopamine release sites
10.1016/j.neuron.2021.10.028 · 2022
Hemiparkinsonism in monkeys after unilateral internal carotid artery artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
10.1016/0024-3205(86)90431-5 · 1986
Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics
10.1371/journal.pbio.2006265 · 2018
Post-translational modification of α-synuclein in Parkinson’s disease
10.1016/j.brainres.2015.06.002 · 2015
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
10.1038/nature10324 · 2011
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
10.1212/wnl.0b013e3182904faa · 2013
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson’s disease and nonhuman primate brains
10.1002/mds.23442 · 2011
Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies
10.1016/j.nbd.2015.03.023 · 2015
Progressive parkinsonism due to mitochondrial impairment: lessons from the MitoPark mouse model
10.1016/j.expneurol.2021.113707 · 2021
Genetic risk factors in Parkinson’s disease
10.1007/s00441-018-2817-y · 2018
Next-Generation Gene Therapy for Parkinson’s Disease Using Engineered Viral Vectors
10.3233/jpd-212674 · 2021
Parkinson’s disease
10.1016/s0140-6736(21)00218-x · 2021
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease
10.1016/s0301-0082(01)00003-x · 2001
Convection-enhanced delivery of macromolecules in the brain
10.1073/pnas.91.6.2076 · 1994
Redox cycling of the herbicide paraquat in microglial cultures
10.1016/j.molbrainres.2004.11.005 · 2005
Efficacy and safety of Safinamide in patients with Parkinson’s disease experiencing motor fluctuations: results of a 6-month Phase III, randomized, double-blind, placebo-controlled study
2009
A highly reproducible rotenone model of Parkinson’s disease
10.1016/j.nbd.2009.01.016 · 2009
Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: the Findings, the Debate, and the Therapeutic Implications
10.3389/fneur.2014.00242 · 2014
A new target for an old DUB: UCH-L1 regulates mitofusin-2 levels, altering mitochondrial morphology, function and calcium uptake
10.1016/j.redox.2020.101676 · 2020
Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
10.1038/s41593-020-0589-7 · 2020
Preparation and properties of a homogeneous aromatic l-amino acid decarboxylase from hog kidney
10.1016/0003-9861(70)90144-x · 1970
Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 trial
10.1212/wnl.0000000000012952 · 2022
Magnetic resonance imaging–guided phase 1 trial of putaminal AADC gene therapy for Parkinson’s disease
10.1002/ana.25450 · 2019
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
10.1212/wnl.0b013e3181c29356 · 2009
Post-mortem studies of neurturin gene therapy for Parkinson’s disease: two subjects with 10 years CERE120 delivery
10.1002/mds.29518 · 2023
Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV α-synucleinopathy
10.1523/jneurosci.5427-08.2009 · 2009
The function of bacterial HtrA is evolutionally conserved in mammalian HtrA2/Omi
2020
Modeling α-synuclein propagation with preformed Fibril injections
10.14802/jmd.19046 · 2019
Activation of the mitochondrial unfolded protein response promotes longevity and dopamine neuron survival in Parkinson’s disease models
10.1038/s41598-017-16637-2 · 2017
Enhanced efficacy of the CDNF/MANF family by Combined intranigral overexpression in the 6-OHDA Rat Model of Parkinson’s disease
10.1038/mt.2014.206 · 2015
Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson’s disease
10.1016/j.molbrainres.2004.06.029 · doi-reference
ShRNA targeting α-synuclein prevents neurodegeneration in a Parkinson’s disease model
10.1172/jci64502 · doi-reference
Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration
10.1016/j.nbd.2019.01.004 · doi-reference
Adeno-associated virus Type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson’s disease
10.1159/000334527 · doi-reference
Mutant alpha-synuclein causes age-dependent neuropathology in monkey brain
10.1523/jneurosci.0772-15.2015 · doi-reference
A CRISPR monkey model unravels a unique function of PINK1 in primate brains
10.1186/s13024-019-0321-9 · doi-reference
DJ-1 inhibits α-synuclein aggregation by regulating chaperone-mediated autophagy
10.3389/fnagi.2017.00308 · doi-reference
Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice
10.1073/pnas.1712648115 · doi-reference
Synuclein activates microglia in a model of Parkinson’s disease
10.1016/j.neurobiolaging.2007.04.006 · doi-reference
Gene therapy for Parkinson’s disease: trials and technical advances
10.1016/s1474-4422(25)00125-5 · doi-reference
Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease
10.1093/brain/awz023 · doi-reference
What do clinical trials tell us about treating patients?
10.1016/s1353-8020(09)70776-x · doi-reference
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes
10.1212/wnl.0b013e31825dcdc1 · doi-reference
Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration
10.1186/s40478-019-0696-4 · doi-reference
Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression
10.1371/journal.pone.0179476 · doi-reference
Neuroprotective role of CHCHD2 in Parkinson’s disease: insights into the GPX4-related ferroptosis pathway
10.1016/j.freeradbiomed.2024.11.034 · doi-reference
Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice
10.7554/elife.28377 · doi-reference
How can rAAV ‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson’s disease?
10.1111/jnc.13627 · doi-reference
ATP13A2 deficiency disrupts lysosomal polyamine export
10.1038/s41586-020-1968-7 · doi-reference
An update on gene therapy approaches for Parkinson’s disease: restoration of dopaminergic function
10.3233/jpd-212724 · doi-reference
Intraputaminal delivery of adeno-associated virus serotype 2–glial cell line–derived neurotrophic factor in mild or moderate Parkinson’s disease
10.1002/mds.30193 · doi-reference
Viral vector-based models of Parkinson’s disease
10.1007/7854_2014_310 · doi-reference
Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36
10.1086/319522 · doi-reference
Elie Chalhoub, The understanding of Parkinson’s disease through genetics and new therapies
10.1002/brb3.2577 · doi-reference
Autophagy and UPS pathway contribute to nicotine-induced protection effect in Parkinson’s disease
10.1007/s00221-023-06765-9 · doi-reference
Drosophila Ubiquitin C-Terminal Hydrolase Knockdown Model of Parkinson’s Disease
10.1038/s41598-018-22804-w · doi-reference
Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson’s disease
10.1016/j.nbd.2014.01.009 · doi-reference
Initial treatment of Parkinson’s disease
10.1007/s11940-006-0013-y · doi-reference
Rotenone, paraquat, and Parkinson’s disease
10.1289/ehp.1002839 · doi-reference
Recent developments in gene therapy for Parkinson’s disease
10.1016/j.ymthe.2025.03.030 · doi-reference
The clinical symptoms of Parkinson’s disease
10.1111/jnc.13691 · doi-reference
10.1089/hum.2004.15.1177
10.1089/hum.2004.15.1177 · doi-reference
Loss of FBXO7 results in a Parkinson’s‐like dopaminergic degeneration via an RPL23–MDM2–TP53 pathway
10.1002/path.5312 · doi-reference
Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease
10.1007/s00441-017-2704-y · doi-reference
TheE3ubiquitin ligase SCF(Fbxo7) mediates proteasomal degradation of UXT isoform 2 (UXT-V2) to inhibit the NF-κB signaling pathway
10.1016/j.bbagen.2020.129754 · doi-reference
Synaptic vesicle recycling pathway determines neurotransmitter content and release properties
10.1016/j.neuron.2019.03.031 · doi-reference
Nigral ATP13A2 depletion induces Parkinson’s disease-related neurodegeneration in a pilot study in non-human primates
10.1038/s41531-024-00757-4 · doi-reference
Glitazone treatment rescues phenotypic deficits in a fly model of Gaucher/Parkinson’s Disease
10.3390/ijms222312740 · doi-reference
Homeostatic p62 levels and inclusion body formation in CHCHD2 knockout mice
10.1093/hmg/ddab057 · doi-reference
sAugmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies
10.1073/pnas.1220464110 · doi-reference